…, JM Jürgensmeier, M Shibuya, SR Wedge… - Molecular Cancer …, 2011 - AACR Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases. This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-associated kinases c-Kit, PDGFR-α, ... Cited by 1 - Related articles - All 3 versions
[PDF] from dbkgroup.orgM Brown, DC Wedge, R Goodacre, DB Kell… - …, 2011 - Oxford Univ Press Results: Three workflows have been developed to allow for the rapid, automated and high-throughput annotation and putative metabolite identification of electrospray LC-MS-derived metabolomic datasets. The collection of workflows are defined as PUTMEDID_LCMS and perform ... Cited by 4 - Related articles - All 7 versions
…, P Steel, L Ayash, M Abidi, J Wedge… - Biology of Blood and …, 2011 - bbmt.org Biology of Blood and Marrow Transplantation, Volume 17, Issue 2, Pages S158-S159, February 2011, Authors:LG Lum; A. Thakur; V. Ratanatharathorn; Z. Al-Kadhimi; E. Paul; C. Skuba; P. Steel; L. Ayash; M. Abidi; J. Wedge; JP Uberti. ... Cached - All 2 versions
…, K McDaid, NR Smith, HM Weir, SR Wedge… - Molecular Cancer …, 2011 - AACR Inhibition of VEGFR-2 signaling reduces angiogenesis and retards tumor growth. Current biotherapeutics that inhibit VEGFR-2 signaling by either sequestering VEGF ligand or inhibiting VEGF binding to VEGFR-2 may be compromised by high VEGF concentrations. Here we describe a ... Cited by 2 - Related articles - All 3 versions
CE Eyers, C Lawless, DC Wedge, KW Lau… - Molecular & Cellular …, 2011 - ASBMB Claire E. Eyers§2, Craig Lawless§1, David C. Wedge§1,3, King Wai Lau1, Simon J. Gaskell2, Simon J. ... §These authors contributed equally to this work ... 1Michael Smith Building, Faculty of Life Sciences,The University of Manchester, Manchester M13 9PT